Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS). A phase III trial suggests that adding moderate regional hyperthermia (HT) to anthracycline-based chemotherapy, followed by surgery and radiotherapy (RT), can improve 10-year overall survival by 10%. This trial aims to optimize treatment by combining the most effective regimens from chemotherapy, HT, RT, and surgery, and will evaluate the feasibility of this new total neoadjuvant treatment (TNT) approach.

Trial Details

NCT ID
NCT06835049
Phase
PHASE2
Sponsor
Swiss Cancer Institute
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Doxorubicin
  • Ifosfamide
  • Dacarbazine
  • Hyperthermia
  • Radiotherapy
  • Surgery
Locations (sample)
  • Aarau, Switzerland|47.39254,8.04422
  • Basel, Switzerland|47.55839,7.57327
  • Bellinzona, Switzerland|46.19278,9.01703
  • Bern, Switzerland|46.94809,7.44744
  • Lausanne, Switzerland|46.516,6.63282

Key Eligibility Criteria

  • Histologically confirmed primary high-risk Soft tissue sarcoma (STS) of extremity or trunk.
  • High-risk according to the prognostic Sarculator tool: 10-year OS probability \< 60%5.
  • Resectable tumor: resectability is based on pre-operative imaging and has to be defined by the local treating sarcoma team. A patient is not consid…
  • Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →